ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
•27 May 2024 00:18

Merger Arb Mondays (27 May) - L'Occitane, SciClone, GA Pack, KFC Japan, CF Logistics, Best World

This week, the highest gross spreads are HEC Pharma (107.6%), Hollysys (19.3%), Ansarada (13.1%), Malaysia Airports (9.6%), China TCM (8.7%),...

Logo
550 Views
Share
bullish•Eoflow
•26 May 2024 07:00

Last Week in Event SPACE: Mitsui Matsushima, L'Occitane, Prosus/Tencent, EOFlow

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
730 Views
Share
bullish•BHP Group Ltd
•25 May 2024 15:00

(Mostly) Asia-Pac M&A: KFC Holdings Japan, Shanghai Henlius, Alumina, BHP/ Anglo American, SciClone

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
798 Views
Share
•23 May 2024 14:40

Henlius Biotech (2696 HK): Fosun Offer?

IF Fosun wants to take the company private, an Offer Price of $26/share, may get the job done. $30/share would be optically be more preferable.

Logo
485 Views
Share
•20 May 2024 00:15

Merger Arb Mondays (20 May) - L'Occitane, China TCM, SciClone, Malaysia Airports, I'rom, Hollysys

This week, the highest gross spreads are HEC Pharma (84.7%), Hollysys (16.5%), QV Equities (9.1%), Ansarada (8.7%), Malaysia Airports (8.3%), China...

Logo
637 Views
Share
x